Addressing Yet Another Challenge In Chronic Care, Curant Health and Johns Hopkins School of Medicine Collaborate on IBD Study – A.L.I.V.E.

Curant Health, provider of innovative medication management services, is currently participating in a study with the Meyerhoff Inflammatory Bowel Disease Center of the Johns Hopkins University School of Medicine to “implement and evaluate the effectiveness of an Inflammatory Bowel Disease (IBD) Medication Therapy Management (MTM) patient fulfillment model compared to standard care in a large university hospital setting.”

What are the study objectives? Improving quality of life, adherence & reducing readmissions

  • To improve symptoms as measured by the Dudley IBD Symptom Questionnaire (DISQ) and quality of life as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ)
  • To decrease hospital readmission rates for patients with IBD
  • To improve adherence rates for IBD therapy
  • To assess smoking rates among these patients with IBD

Addressing a $1.84 billion annual cost to U.S. healthcare

According to our colleague, Principal Investigator and Assistant Professor of Medicine at Johns Hopkins University Dr. Sharon Dudley-Brown, Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, debilitating conditions that can have important economic and clinical implications. In 2004, the annual cost of IBD in the United States was estimated at $1.84 billion. IBD is associated with high morbidity, loss of work productivity and impaired quality of life.

Crohn’s disease and ulcerative colitis are chronic, debilitating conditions. People living with Crohn’s disease and ulcerative colitis have average healthcare costs of $18,963 and $15,020, respectively(1), significantly higher than the $5,000 estimated for the patients in the matched comparison group of similar patients living outside the United States. A 2008 study of the direct healthcare costs of treating Crohn’s and ulcerative colitis found that costs for patients under 20 were higher than those for older adults, “suggesting that focusing on effective management of IBD in pediatric patients could yield significant cost-efficient benefits.”(2)

Curant Health CEO Patrick Dunham told Medcity News, “Our enhanced medication therapy management services are proven to reduce readmissions rates and improve adherence to medication regimens for chronically ill patients. Continuing to validate our work alongside Dr. Dudley-Brown and her colleagues, and most importantly improving the lives of people suffering from chronic conditions like IBD, is central to our mission.”

Why is it important to look at MTM and its effects on adherence rates for patients with IBD?

Increasingly recognized in the healthcare community is the absence of long-run reports on CD or UC. Therefore, data on Adverse Drug Events (ADE’s), hospital readmissions, and long-run adherence rates among these patients is currently very limited. An integrated MTM platform will allow for tackling these issues and evaluating the impact on IBD patients’ clinical outcomes. Read more from IBD News Today.

If you would like to know more about this study, including information on results as they become available, or more about Curant Health’s medication management programs proven to improve medication adherence, reduce hospital readmissions, reduce costs and improve patient outcomes, please contact Curant Health Director of Commercial Strategy and Performance, Jake Caines, at